Investor Overview

Overview

Investor Presentation

Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer (also known as TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density.

Tricida’s New Drug Application (NDA) for veverimer is currently under review by the U.S. Food and Drug Administration (FDA). The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 22, 2020.*

Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.

*Please review our Forward Looking Statements for information regarding the risks and uncertainties related to these statements.

SEC Filings

Filing date Description Form View

Statement of changes in beneficial ownership of securities

 4 View HTML
0001595585-19-000263.pdf
0001595585-19-000263.rtf

Statement of changes in beneficial ownership of securities

 4 View HTML
0001595585-19-000264.pdf
0001595585-19-000264.rtf

Statement of changes in beneficial ownership of securities

 4 View HTML
0001595585-19-000262.pdf
0001595585-19-000262.rtf

Report of unscheduled material events or corporate event

 8-K View HTML
0001595585-19-000257.pdf
0001595585-19-000257.rtf
0001595585-19-000257.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

Quarterly report which provides a continuing view of a company's financial position

 10-Q View HTML
0001595585-19-000259.pdf
0001595585-19-000259.rtf
0001595585-19-000259.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

Stock Information

Change
Volume
52 Week High
52 Week Low

Copyright West LLC. Minimum 15 minutes delayed.

FAQs

Show All
Where is Tricida’s corporate headquarters?
Tricida, Inc.
7000 Shoreline Court, Suite 201
South San Francisco, CA 94080
When was Tricida founded?
Tricida was founded in August of 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases.
Where is Tricida incorporated?
Tricida, Inc., is incorporated in Delaware.
When did Tricida go public?
Tricida commenced its initial public offering (IPO) in June 2018.
How is Tricida’s stock traded?
Tricida’s common stock is listed on the NASDAQ Global Select Market under the symbol TCDA.
What is Tricida’s fiscal year?
Tricida’s fiscal year ends December 31st.
Who is Tricida’s transfer agent and how do I contact them about stock-related inquiries?

Computershare Trust Company, N.A. is the transfer agent and registrar for the common stock of Tricida. Please contact Computershare as follows:

Regular Delivery:
Computershare
P.O. Box 505000
Louisville, KY 40233-5000

By Overnight Delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Online:
Computershare Investor Services:
www.computershare.com/investor

Phone:
(800) 736-3001 (US, Canada, Puerto Rico)
(781) 575-3100 (non-US)

Email:
web.queries@computershare.com

How do I transfer stock, change the address on my shareholder account, or replace a lost stock certificate?

To change the address on your shareholder account you must send both your old and new addresses to our transfer agent at the following address:

Computershare
462 South 4th Street
Louisville, KY 40202

Does Tricida have a direct stock purchase plan?
Tricida does not have a direct stock purchase plan.
Who is Tricida’s auditor?
The auditor for Tricida is Ernst and Young LLP.
Whom should I contact for investor inquiries?
Please send investor inquiries to IR@Tricida.com.
See more FAQs...